China’s biomanufacturing strategy is accelerating efforts to turn biotechnology breakthroughs into commercial products across medicines, food, energy and advanced materials.
BEIJING: China’s biomanufacturing strategy is moving into a new phase as the government seeks breakthrough products that can turn biotechnology research into industrial-scale businesses and create new sources of economic growth.
China’s Ministry of Industry and Information Technology (MIIT) announced the 2026 initiative on September 24, calling for submissions of flagship biomanufacturing products from across the country. The programme forms part of Beijing’s broader effort to accelerate technological innovation and commercialisation.
What does China want to develop?
The initiative covers a broad range of biotechnology applications rather than focusing solely on pharmaceuticals.
Priority areas include food and food additives, upstream biopharmaceutical materials, cosmetics, bio-based chemicals, bioenergy, bio-based materials, enzymes, biosynthesis of natural products and specialised manufacturing equipment.
MIIT is seeking products that demonstrate advanced technology, clear economic benefits and strong potential for wider adoption.
The programme divides potential flagship products into four groups, including products that could overcome technological bottlenecks, innovative products with major commercial potential and technologies capable of replacing conventional manufacturing processes.
Why is China expanding biomanufacturing?
China views biotechnology and biomanufacturing as potential engines for future industrial growth.
The government wants to accelerate breakthroughs across the entire innovation chain, helping promising laboratory research move towards manufacturing and commercial applications.
China’s biomanufacturing strategy also reflects the country’s wider emphasis on developing advanced industries where scientific research, manufacturing capacity and emerging technologies can combine to create new markets.
The latest programme specifically calls for original and potentially disruptive technologies while seeking to accelerate the conversion of innovation into what the ministry describes as real productive capacity.
Beijing attracts new biotechnology investment
Separate developments in Beijing underline the scale of investment flowing into the sector.
Eight major biotechnology and healthcare projects have recently been announced for the Beijing Economic-Technological Development Area. They include research, manufacturing, artificial intelligence and pharmaceutical projects involving domestic and international companies.
The projects are expected to strengthen Beijing’s biotechnology and healthcare cluster while attracting additional international innovation resources.
What happens next?
Provincial and regional industry authorities will identify and recommend qualifying products under the national programme.
The initiative could help promising biotechnology businesses gain greater visibility while encouraging companies to move emerging technologies from research towards large-scale production.
China’s biomanufacturing strategy ultimately aims to develop commercially valuable products capable of supporting new industries rather than leaving biotechnology breakthroughs confined to laboratories.
Impact to expect
The initiative could accelerate investment and commercialisation across China’s biotechnology sector while strengthening the country’s position in emerging areas such as bio-based materials, pharmaceuticals, sustainable chemicals and advanced manufacturing.
